Atom Bioscience Initiates Enrolment in Global P-IIb/III Study of ABP-671 to Treat Chronic Gout in US
Shots:
- Atom Bioscience initiated patient enrolment in the US for a P-IIb/III study of ABP-671 in oral formulation to treat Chronic Gout
- P-IIb/III study (n=580) evaluates ABP-671 in two parts; Part 1 for safety and efficacy at different doses and regimens vs PBO or allopurinol (SOC) in the US; Part 2 for comparing dose regimens selected from Part 1 with PBO in patients who were not enrolled in Part 1; identified 36 sites in 17 states
- ABP-671, an orally administered URAT1 inhibitor; preclinical data showed significant efficacy and good safety, whereas existing drugs showed poor efficacy and SAEs (incl. kidney failure, sudden cardiac death, or severe liver toxicity)
Ref: Atom Bioscience | Image: Atom Bioscience
Related News:- Alvotech and Teva Pharmaceuticals Collaborate to Expand Access for Adalimumab-ryvk (Interchangeable Biosimilar, Humaira) in US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
